Ann: New Phase I/II Clinical Trial in Children with PANDAS/PANS, page-5

Very ambiguous clinical and diagnostic rigor around this 'condition' and its origins and treatment options
Neuroinflammation is a contributing marker / potential trigger for the associated behavioural 'abnormalities' being attributed to panda/pans

https://www.spectrumnews.org/features/deep-dive/how-a-controversial-condition-called-pandas-is-gaining-ground-on-autism/

lot of conjecture about the size of the addressable market ....some reported figures suggest 1 in 200 children across the US ....these numbers are hotly contested though

https://www.bannerhealth.com/healthcareblog/teach-me/does-my-child-have-pandas

not a research pathway I'de have nominated as the next stepping stone to product registration / commercialisation for these reasons....though I suspect it is riding on the back of the exceptional pediatric asd study outcomes achieved so far

speaking of which an update would be nice and is now overdue